Correct Answer: B. Dicloxacillin
Mastitis in lactating mothers is predominantly caused by Staphylococcus aureus (60–80% of cases), with Streptococcus agalactis and Escherichia coli accounting for the remainder. The first-line antibiotic must achieve high breast tissue penetration, cover S. aureus reliably, and be safe for the nursing infant. Dicloxacillin is a beta-lactamase-resistant penicillin (isoxazolyl penicillin) that meets all three criteria: it achieves excellent concentrations in breast milk and breast tissue, provides reliable coverage against penicillinase-producing S. aureus (the most common pathogen), and is considered safe in lactation (minimal infant absorption, no teratogenicity). The typical dose is 500 mg orally four times daily for 10–14 days. Early initiation of antibiotics, combined with continued breastfeeding (which aids drainage and prevents abscess formation), reduces progression to breast abscess from ~11% to <5%. Dicloxacillin's oral bioavailability and favorable pharmacokinetics in lactation make it the preferred first-line agent in Indian clinical practice and international guidelines (ACOG, RCOG). Cultures are not routinely obtained unless the patient fails to respond within 48–72 hours or presents with systemic toxicity.
Why the other options are wrong
A. Ceftriaxone — Ceftriaxone is a third-generation cephalosporin reserved for severe, hospital-acquired, or polymicrobial infections. It is not first-line for uncomplicated lactational mastitis because: (1) it is overkill for S. aureus coverage, (2) it requires parenteral administration (not practical for outpatient management), (3) it achieves lower breast tissue penetration than dicloxacillin, and (4) it increases risk of Clostridioides difficile colitis. NBE may use this to test whether students confuse severity with antibiotic choice. C. Ampicillin — Ampicillin is a broad-spectrum penicillin but lacks beta-lactamase resistance. Since 40–50% of S. aureus strains in India produce beta-lactamase, ampicillin will fail in nearly half of mastitis cases. It is not suitable as first-line therapy. This is a classic NBE trap: ampicillin looks like a reasonable penicillin choice but lacks the critical resistance mechanism needed for reliable S. aureus coverage in lactational mastitis. D. Cefazolin — Cefazolin is a first-generation cephalosporin with good S. aureus coverage and reasonable breast tissue penetration. However, it requires parenteral (IV/IM) administration, making it impractical for outpatient management of uncomplicated mastitis. Dicloxacillin's oral route, equivalent efficacy, and lower cost make it superior. Cefazolin is reserved for severe cases or when oral therapy fails.
High-Yield Facts
- Staphylococcus aureus causes 60–80% of lactational mastitis; beta-lactamase-resistant penicillins are first-line.
- Dicloxacillin 500 mg QID for 10–14 days is the standard first-line DOC; oral bioavailability and breast tissue penetration are excellent.
- Continue breastfeeding during mastitis treatment; it aids drainage, prevents abscess, and is safe with dicloxacillin.
- Failure to respond in 48–72 hours suggests abscess formation, resistant organism, or poor compliance; obtain culture and consider imaging (ultrasound).
- Beta-lactamase-producing S. aureus prevalence in India is 40–50%; ampicillin alone is inadequate.
Mnemonics
MASTITIS FIRST-LINE: DIOXO Dicloxacillin (or Flucloxacillin in some regions) — Isoxazolyl penicillin — Oral — Xanthus (resistant to beta-lactamase) — Outpatient safe. Use when you see 'lactating mother + mastitis' in the stem. Why NOT Ampicillin in Mastitis Ampicillin = All S. aureus NOT covered (beta-lactamase producers escape). Dicloxacillin = Diclox = Defends against beta-lactamase.
NBE Trap
NBE pairs 'lactating mother' with broad-spectrum agents (ceftriaxone, cefazolin) to lure students into choosing 'stronger' antibiotics. The trap is confusing antibiotic potency with appropriateness: mastitis is usually uncomplicated, community-acquired S. aureus, and requires targeted (not empiric broad-spectrum) therapy with oral bioavailability.
Clinical Pearl
In Indian outpatient OBG practice, a lactating mother presenting with breast pain, erythema, and fever within 2–3 weeks postpartum is mastitis until proven otherwise. Starting dicloxacillin immediately (without waiting for culture) and reassuring her to continue breastfeeding prevents progression to abscess and reduces readmission. If fever persists beyond 48–72 hours despite compliance, ultrasound the breast to rule out abscess and consider culture-guided therapy.
_Reference: OP Ghai (Pediatrics, lactation section); DC Dutta (Obstetrics, Ch. 23 — Puerperium); Harrison Ch. 127 (Staphylococcal infections)_